Mega Genomics (HKSE:06667) Equity-to-Asset : 0.81 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mega Genomics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$705.3 Mil. Mega Genomics's Total Assets for the quarter that ended in Dec. 2023 was HK$871.2 Mil. Therefore, Mega Genomics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.81.

The historical rank and industry rank for Mega Genomics's Equity-to-Asset or its related term are showing as below:

HKSE:06667' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01 Med: 0.81 Max: 0.9
Current: 0.81

During the past 5 years, the highest Equity to Asset Ratio of Mega Genomics was 0.90. The lowest was -0.01. And the median was 0.81.

HKSE:06667's Equity-to-Asset is ranked better than
84.55% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58 vs HKSE:06667: 0.81

Mega Genomics Equity-to-Asset Historical Data

The historical data trend for Mega Genomics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Equity-to-Asset Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.01

0.39

0.90

0.88

0.81

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.90	0.87	0.88	0.89	0.81

Competitive Comparison of Mega Genomics's Equity-to-Asset

For the Diagnostics & Research subindustry, Mega Genomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mega Genomics's Equity-to-Asset falls into.

Mega Genomics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mega Genomics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	705.298	/	871.241
	=	0.81

Mega Genomics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	705.298	/	871.241
	=	0.81

Mega Genomics (HKSE:06667) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Mega Genomics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics (HKSE:06667) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.

Executives

Guo Meiling	2101 Beneficial owner
Lin Lin	2101 Beneficial owner
Yu Rong	2501 Other
Infinite Galaxy Health Limited	2101 Beneficial owner
Mei Nian Investment Limited	2101 Beneficial owner
Kastle Limited	2501 Other
Mega Marvelous Limited	2501 Other
Yurong Technology Limited	2101 Beneficial owner
Niu Zhencai	2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines